The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,322.00
Bid: 2,321.00
Ask: 2,323.00
Change: -6.00 (-0.26%)
Spread: 2.00 (0.086%)
Open: 2,313.00
High: 2,338.00
Low: 2,312.00
Prev. Close: 2,328.00
HLMA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

23 Mar 2022 07:00

RNS Number : 6634F
Halma PLC
23 March 2022
 

Trading update

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner and healthier future, today releases its scheduled trading update, for the period from 1 October 2021 to date.

Good progress in the second half and substantial growth in the year as a whole

Halma has made good progress in the second half of the financial year to date. We continue to benefit from our strong purpose, our diverse portfolio, and our resilient, long-term growth drivers. These strategic qualities, together with the essential nature of many of our products and services, have underpinned increasing demand across the Group. The Board expects Adjusted profit before taxation for the year ending 31 March 2022 to be in line with market consensus expectations (see notes 1 and 2).

The Group is expected to deliver a further sequential improvement in revenue in the second half of the year and substantial revenue growth in the year as a whole. Order intake has continued to be ahead of both revenue this year and order intake for the same period last year.

As planned, we increased strategic investment in talent, new product development, information technology and cybersecurity, to support our growth over the longer term. We also saw a return of discretionary overhead costs to support our current strong growth. Therefore, as guided at the half-year, full year return on sales is anticipated to be more in line with historical levels.

The agility of our business model has enabled our companies to respond effectively to the range of operational challenges caused by COVID-19 and, more recently, the effects of Russia's invasion of Ukraine (see note 4).

The Group has a strong financial position, which enables continued investment, both organically and by acquisition, to support continued growth. Cash generation was solid, and reflected the strong growth in the period and investment to maintain resilience in our supply chain.

Organic constant currency revenue growth in all sectors and major geographic regions

There was further organic constant currency revenue growth across all sectors in the period, following a strong first half. There was widespread growth geographically in the period, with the strongest performances (on an organic constant currency basis) in the USA and the UK, and good growth in Mainland Europe and Asia Pacific.

The Environmental & Analysis sector has continued to deliver strong organic constant currency revenue growth. This reflects ongoing high demand for its products and services, particularly for technologies that support the building of digital and data infrastructure, and for gas monitoring products.

The Safety and Medical sectors are expected to report good organic constant currency revenue growth, also against a strong comparative. On a reported basis, the Medical sector's revenue growth will also benefit from recent acquisitions, while the Safety sector's progress will see the impact of the disposal of Texecom made in the first half of the year.

The strength of Sterling is having a negative currency translation effect on the Group's results (see note 5).

Further progress in M&A; healthy acquisition pipeline

We have made three further acquisitions in the second half of the financial year, bringing the total number of acquisitions made in the year to date to 13 for an aggregate maximum consideration of £166 million (see note 6).

Our acquisition pipeline remains healthy across all three sectors. We continue to actively manage our portfolio of global businesses to ensure that it continues to deliver strong growth and returns over the long term and is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day.

Full Year Results

The results for the full year ending 31 March 2022 will be released on Thursday 16 June 2022.

For further information, please contact:

Halma plc

Andrew Williams, Group Chief Executive +44 (0)1494 721111

Marc Ronchetti, Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP Communications

Andrew Jaques / Rachel Farrington +44 (0)20 3128 8613

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.

Its purpose defines the three broad market areas where it operates:

· Safety: protecting life as populations grow and protecting worker safety.

· Environment: addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health: meeting rising healthcare demand as growing populations age and lifestyles change.

It employs over 7,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

In January 2022, Halma was named one of Britain's Most Admired Companies by Management Today.

Notes:

1: Adjusted profit before tax is before amortisation and impairment of acquired intangible assets, acquisition items, restructuring costs and profit or loss on disposal of businesses.

2. The Board believes current market forecasts for Adjusted profit before tax for the year ending 31 March 2022 to be in the range of £300.7m to £313.4m, with a consensus of £306.5m.

3. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

4. Our direct operational exposure to Russia and Ukraine is low. All Halma group companies have ceased sales into Russia following its invasion of Ukraine and we have no companies, facilities or direct employees in either country. In the current financial year, sales to Russia have represented less than 0.5% of group revenues, with revenue in Ukraine being insignificant. We have no significant dependency on direct supplies of components or materials from either Russia or Ukraine and, where we do have suppliers, we are finding alternative sources.

Our thoughts are with everyone whose lives have been affected by the Russian invasion of Ukraine. We are supporting the employees in our companies whose families are affected, as well as matching any donations made by our companies and colleagues to the International Committee of the Red Cross.

5. Sterling has strengthened in the year relative to many currencies, including the US Dollar and Euro. If current exchange rates continue throughout the rest of the current financial year, the currency translation impact on the Group's results is expected to be negative. Based on exchange rates of Sterling/US Dollar 1:1.37 and Sterling/Euro 1:1.18, we would expect approximately a £41m negative revenue effect and approximately a £9m negative profit effect, compared to the 2021 financial year.

6. We made ten acquisitions and a disposal in the first half of the financial year, details of which are contained in our Half Year Results announcement, which was released on 18 November 2021.

We have completed three acquisitions in the second half of the year to date:

· Clayborn Lab, a provider of custom heat tape solutions primarily for heated sample lines in the environmental monitoring market, for an initial cash consideration of US$4.5m (£3.3m) with an additional earn-out consideration of US$1.5m (£1.1m);

· Infinite Leap, a healthcare consulting and services provider for real-time location technologies, for an initial cash consideration of US$30m (approximately £22m), on a cash and debt free basis, and additional earn-out considerations of up to an aggregate maximum of US$17m (approximately £13m);

· International Light Technologies, Inc., a leading developer of technical lighting sources and light measurement systems for US$26.6m (approximately £19.5m) on a cash and debt free basis.

7. A copy of this announcement, together with other information about Halma, may be viewed on its website at www.halma.com.

=================

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEWFWEEESEFD
Date   Source Headline
28th May 20123:22 pmRNSDirector Declaration
14th May 201210:55 amRNSHolding(s) in Company
11th May 20123:15 pmRNSHolding(s) in Company
2nd May 20123:48 pmRNSTotal Voting Rights
1st May 20126:22 pmRNSTreasury Stock
2nd Apr 201210:20 amRNSTotal Voting Rights
1st Mar 201210:24 amRNSTotal Voting Rights
28th Feb 20127:00 amRNSChange of Adviser
23rd Feb 20122:15 pmRNSDirector/PDMR Shareholding
21st Feb 20123:08 pmRNSAdditional Listing
16th Feb 20127:00 amRNSInterim Management Statement
10th Feb 20129:38 amRNSTreasury Stock
9th Feb 201211:33 amRNSTreasury Stock
8th Feb 201210:32 amRNSTreasury Stock
3rd Feb 201212:22 pmRNSTreasury Stock
2nd Feb 20122:56 pmRNSTotal Voting Rights
24th Jan 20124:42 pmRNSBlocklisting Interim Review
3rd Jan 20124:57 pmRNSTotal Voting Rights
1st Dec 20114:40 pmRNSTotal Voting Rights
22nd Nov 20112:25 pmRNSDoc re. Half Year Report 2011/12
22nd Nov 20117:00 amRNSHalf Yearly Report
21st Nov 201111:08 amRNSDirector Declaration
14th Nov 20113:46 pmRNSHolding(s) in Company
14th Nov 20113:44 pmRNSNotice of Results
11th Nov 20117:00 amRNSDirectorate Change
2nd Nov 201112:56 pmRNSDirector Declaration
1st Nov 201111:12 amRNSTotal Voting Rights
17th Oct 20114:06 pmRNSHolding(s) in Company
11th Oct 20113:35 pmRNSHolding(s) in Company
6th Oct 20112:54 pmRNSDirector/PDMR Shareholding
3rd Oct 201110:41 amRNSTotal Voting Rights
15th Sep 201112:47 pmRNSDirector/PDMR Shareholding
1st Sep 201112:47 pmRNSTotal Voting Rights
26th Aug 20112:32 pmRNSBlocklisting Interim Review
16th Aug 20115:19 pmRNSAnnual Information Update
12th Aug 20114:43 pmRNSShare transactions and Purchase of Own Shares
8th Aug 201112:48 pmRNSTreasury Stock
1st Aug 20112:40 pmRNSTotal Voting Rights
29th Jul 20112:10 pmRNSDirectorate Change
29th Jul 20111:20 pmRNSResult of AGM
28th Jul 20117:00 amRNSAGM Statement
12th Jul 201110:13 amRNSDirector/PDMR Shareholding
11th Jul 20119:25 amRNSAcquisition
1st Jul 201111:55 amRNSTotal Voting Rights
28th Jun 20114:06 pmRNSDirector/PDMR Shareholding
27th Jun 201112:45 pmRNSAnnual Financial Report
21st Jun 20117:00 amRNSFinal Results
14th Jun 20119:24 amRNSNotice of Results
2nd Jun 201111:51 amRNSTotal Voting Rights
10th May 20119:00 amRNSAcquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.